Osteoporosis: The Dynamic Relationship between Magnesium and Bone Mineral Density in the Heart Transplant Patient

Critical Care Nursing Quarterly

Volumn 27, Issue 1, 2004, Pages 96-100

  Launius, Beatrice K ^a,c   Brown, Patricia A ^b   Cush, Eleanor M ^a   Mancini, Mary C ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Willis Knighton Medical Center   (United States)

^c NONE   (United States)

Author keywords

Bone mineral density; Cyclosporine; Heart transplant; Magnesium; Osteoporosis; Parathyroid hormone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; CYCLOSPORIN; RISEDRONIC ACID;

BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; EXERCISE; FEMUR FRACTURE; FEMUR NECK; HEART TRANSPLANTATION; HORMONE SUBSTITUTION; HUMAN; HYPOMAGNESEMIA; OSTEOBLAST; OSTEOPOROSIS; PATHOGENESIS; RECIPIENT; REVIEW; VERTEBRA FRACTURE;

EID: 0842304729     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-200401000-00010     Document Type: Review

References (26)

1. Fitzgerald PA. Endocrinology. In: Tierney LM, McPhee SJ, Papadakis MA, eds. Current Medical Diagnosis and Treatment. 40th ed. New York: Lange Medical Books; 2001:1088-1160.
2. National Osteoporosis Foundation. Disease statistics. Available at: www.nof.org/osteoporosis/stats.htm. Accessed September 24, 2003.
3. Kessenich CR. Prevent corticosteroid-induced osteoporosis. Nurse Pract., 2002;27(4):15.
4. United Network for Organ Sharing. Immunosuppression used for maintenance prior to discharge, 1992 to 2000. Available at: www.optn.org/data/annual/Report.asp?url=/Data/ar2002/ar02_table_1106_maint_HR. Accessed September 24, 2003.
5. Stempfle H-U, Werner C, Echtler S, et al. Prevention of osteoporosis after cardiac transplantation. Transplantation. 1999;68:523-530.
6. Guo C-Y, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone. 1998;22:267-271.
7. Muchmore JS, Cooper KC, Ye Y, Schlegel V, Pribil A, Zuhdi N. Prevention of loss of vertebral bone density in heart transplant patients. J Heart Lung Transplant. 1992;11:959-964.
8. Glendenning P, Kent GN, Adler BD, et al. High prevalence of osteoporosis in cardiac transplant recipients and discordance between biochemical turnover markers and bone histomorphometry. Clin Endocrinol. 1999;50:347-355.
9. Dodidou P, Bruckner T, Hosch S, et al. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos Int. 2003;14:82-89.
10. Boncimino K, McMahon DJ, Addesso V, Bilezikian JP, Shane E. Magnesium deficiency and bone loss after cardiac transplantation. J Bone Miner Res. 1999;14:295-303.
11. Cremer J, Strüber M, Wagenbreth I, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thorac Surg. 1998:67:130-133.
12. Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia: Saunders; 2000.
13. Shane E, Rodino MA, McMahon DJ, et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant. 1998;17:1089-1096.
14. Rude RK. Magnesium homeostasis. In: Bilezikian JP, Raisz LG, Rodan GA, eds. Principles of Bone Biology. New York: Academic Press; 1996:277-293.
15. Rude RK, Oldham SB, Sharp CF, Singer FR. Parathyroid hormone secretion in magnesium deficiency. J Clin Endocrinol Metab. 1978;47:800-806.
16. Toffaletti J, Cooper DL, Lobaugh B. The response of parathyroid hormone to specific changes in either ionized calcium, ionized magnesium, or protein-bound calcium in humans. Metabolism. 1991;8:814-818.
17. Cholst IN, Steinberg SF, Tropper PJ, Fox HE, Segre GV, Bilezikian JP. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med. 1984;310:1221-1225.
18. Fatemi S, Ryzen E, Flores J, Endres DB, Rude RK, Effect of experimental human magnesium depletion on parathyroid hormone secretion and 1,25 dihydroxyvitamin D metabolism. J Clin Endocrinol Metab. 1991;73:1067-1072.
19. Cyclosporine. Micromedex. Available at: http://172. 16.7.248/mdx/mdxcgi/display.exe?CTL=c:/mdx/mdxcgi/MEGAT.SYS$SET=1. Accessed August 25, 2003.
20. Stein B, Takizawa M, Katz I, et al. Salmon calcitonin prevents cyclosporine-A induced high turnover bone loss. Endocrinology. 1991;129:92-98.
21. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997;82:1497-1506.
22. Rich GM, Mudge GH, Laffel GL, LeBoff MS. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant. 1992;11:950-958.
23. Yamani MH, Starling RC. Long-term medical complications of heart transplantation: information for the primary care physician. Cleve Clin J Med. 2000;67:673-680.
24. Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000;15:1818-1824.
25. Waggoner LE. Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Am J Med Sci. 1997;31:173-184.
26. Henderson K, Eisman J, Keogh A, et al. Protective effect of short-term calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2001;16:565-571.